A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography

Cardiovascular Research

Volumn 39, Issue 1, 1998, Pages 216-223

  Schwarz, Ernst R ^b   Pollick, Charles ^b   Dow, Joan ^b   Patterson, Mike ^b   Birnbaum, Yochai ^b   Kloner, Robert A ^a,b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adriamycin; Cardiomyopathy; Echocardiography; Rats

Indexed keywords

DOXORUBICIN;

ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; COST; DOSE RESPONSE; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSTHORACIC ECHOCARDIOGRAPHY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOMYOPATHY, DILATED; DISEASE MODELS, ANIMAL; DOXORUBICIN; ECHOCARDIOGRAPHY; EVALUATION STUDIES; FEMALE; MICROSCOPY, ELECTRON; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032127180     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00009-1     Document Type: Article

References (34)

1. [1] Smith HJ, Nuttall A. Experimental models of heart failure. Cardiovasc Res 1985;19:181-186.
2. [2] Bristow MR. Toxic cardiomyopathy due to doxorubicin. Hosp Pract 1982;17:101-111.
3. [3] Jackson JA, Reeves JP, Muntz KH, et al. Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol 1984;117:140-153.
4. [4] Lefrak E, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-314.
5. [5] Gilladoga AC, Manuel C, Tan CT, Wollner N, Sternberg SS, Murphy ML. The cardiotoxicity of adriamycin and daunorubicin in children. Cancer 1976;37:1070-1078.
6. [6] Friedman MA, Bozdeck MJ, Billingham ME, Rider AK. Doxorubicin cardiotoxicity: serial endomyocardial biopsies and systolic time intervals. J Am Med Assoc 1978;240:1603-1606.
7. [7] Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981;102:709-718.
8. [8] Bloom KR, Bini RM, Williams CM, Sonley MJ, Gribben MA. Echocardiography in adriamycin cardiotoxicity. Cancer 1978;41:1265-1269.
9. [9] Hutter JJJ, Sahn DJ, Woolfenden JM, Carnahan Y. Evaluation of the cardiac effects of doxorubicin by serial echocardiography. Am J Dis Child 1981;135:653-657.
10. [10] Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989;118:92-98.
11. [11] Arnolda L, McGrath B, Cocks M, Sumithran E, Johnston C. Adriamycin cardiomyopathy in the rabbit; an animal model of low cardiac failure with activation of vasoconstriction mechanisms. Cardiovasc Res 1985;19:378-382.
12. [12] Olson HM, Young DM, Prieur DJ, LeRoy AF, Reagan RL. Electrolyte and morphologic alterations of myocardium in adriamycin-treated rabbits. Am J Pathol 1974;77:439-454.
13. [13] Jaenke RS. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Lab Invest 1974;30:292-304.
14. [14] Hanai K, Takaba K, Manabe S, Nakano M, Kohda A, Matsuo M. Evaluation of cardiac function by echocardiography in dogs treated with doxorubicin. J Toxicol Sci 1996;21:1-10.
15. [15] Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites Alterations produced by doxorubicin. J Clin Invest 1980;65:128-135.
16. [16] Mettler FP, Young DM, Ward JM. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res 1977;37:2705-2713.
17. [17] Pollick C, Hale SL, Kloner RA. Echocardiographic and cardiac Doppler assessment of mice. J Am Soc Echocardiogr 1995;8:602-610.
18. [18] Hagar JM, Matthews R, Kloner RA. Quantitative two-dimensional echocardiographic assessment of regional wall motion during transient ischemia and reperfusion in the rat. J Am Soc Echocardiogr 1995;8:162-174.
19. [19] Pollick C, Fitzgerald PJ, Popp RL. Variability of digitized echocardiography: size, source, and means of reduction. Am J Cardiol 1983;51:576-582.
20. [20] Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on standards, Subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
21. [21] Wakasugi S, Fischman AJ, Babich JW, et al. Myocardial substrate utilization and left ventricular function in adriamycin cardiomyopathy. J Nucl Med 1993;34:1529-1535.
22. [22] Pye MP, Black M, Cobbe SM. Comparison of in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. Cardiovasc Res 1996;31:873-881.
23. [23] Pawlush DG, Moore RL, Musch TI, Davidson WRJ. Echocardiographic evaluation of size, function, and mass of normal and hypertrophied rat ventricles. J Appl Physiol 1993;74:2598-2605.
24. [24] de Simone G, Devereux RB, Wallerson DC. Echocardiographic assessment of left ventricular hypertrophy in rats using a simplified approach. Am J Hypertens 1994;7:555-558.
25. [25] Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS. Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 1995;91:2642-2654.
26. [26] Jones EF, Harrap SB, Calafiore P, Tonkin AM. Development and validation of echocardiographic methods for estimating left ventricular mass in rats. Clin Exp Pharm Physiol 1992;19:361-364.
27. [27] Nakamura T, Kuribayashi T, Shimoo K, Katsume H, Nakagawa M, Komeda T. Echo/Doppler diagnosis of tetralogy of Fallot, ventricular septal defect, pulmonary valve dysplasia, and hypertrophic cardiomyopathy in WKY/NCrj rats. Jpn Circ J 1992;56:441-451.
28. [28] Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994;89:345-354.
29. [29] Devereux RB, Wallerson DC, de Simone G, Ganau A, Roman MJ. Evaluation of left ventricular hypertrophy by M-mode echocardiography in patients and experimental animals. Am J Card Imag 1994;8:291-304.
30. [30] Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJJ. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol 1992;19:394-401.
31. [31] Yeung TK, Simmonds RH, Hopewell JW Time-and dose-related modifications in cardiac function in rats after single intravenous doses of epirubicin. Radiother Oncol 1988;11:263-269.
32. [32] Gorodetskaya EA, Dugin SF, Golikov MA, Kapelko VI, Medvedev OS. The cardiac contractile function and hemodynamic control in rats after adriamycin treatment. Can J Physiol Pharmacol 1990;68:211-215.
33. [33] Lambert C, Mossiat C, Tanniere-Zeller M, Maupoil V, Rochette L. Antiarrhythmic effect of amiodarone on doxorubicin acute toxicity in working rat hearts. Cardiovasc Res 1990;24:653-658.
34. [34] Tong J, Ganguly PK, Singal PK. Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol 1991;260:H909-H916.